GeneDx (NASDAQ:WGS) CFO Sells $47,556.18 in Stock

Key Points

• Kevin Feeley, CFO of GeneDx, sold 378 shares of the company’s stock for a total of $47,556.18, reducing his ownership by 8.45% to 4,096 shares.
• GeneDx reported earnings per share of $0.50 in its latest quarter, significantly beating analysts' expectations of $0.10, with revenue of $102.69 million compared to expectations of $86.00 million.
• Several analysts have recently upgraded GeneDx's stock ratings, with target prices raised to as high as $120.00, indicating a positive outlook for the company’s financial prospects.

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 378 shares of the firm's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $125.81, for a total value of $47,556.18. Following the transaction, the chief financial officer owned 4,096 shares in the company, valued at approximately $515,317.76. This trade represents a 8.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, July 29th, Kevin Feeley sold 388 shares of GeneDx stock. The shares were sold at an average price of $105.31, for a total value of $40,860.28.
• On Wednesday, July 9th, Kevin Feeley sold 5,278 shares of GeneDx stock. The shares were sold at an average price of $93.00, for a total value of $490,854.00.
• On Tuesday, July 1st, Kevin Feeley sold 1,344 shares of GeneDx stock. The shares were sold at an average price of $91.12, for a total value of $122,465.28.

GeneDx Stock Down 0.7%

NASDAQ:WGS traded down $0.96 during trading hours on Wednesday, hitting $127.22. 341,722 shares of the company traded hands, compared to its average volume of 1,041,267. The company has a quick ratio of 2.70, a current ratio of 2.87 and a debt-to-equity ratio of 0.19. The firm's 50-day simple moving average is $101.77 and its 200-day simple moving average is $90.34. GeneDx Holdings Corp. has a one year low of $28.86 and a one year high of $131.00. The company has a market cap of $3.66 billion, a PE ratio of 2,544.40 and a beta of 2.04.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.40. GeneDx had a return on equity of 16.51% and a net margin of 0.39%.The business had revenue of $102.69 million for the quarter, compared to analysts' expectations of $86.00 million. GeneDx has set its FY 2025 guidance at EPS. Equities analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Wall Street Analysts Forecast Growth

WGS has been the topic of a number of recent analyst reports. Wells Fargo & Company lifted their target price on GeneDx from $78.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 30th. Guggenheim reissued a "buy" rating and issued a $115.00 price objective (up previously from $88.00) on shares of GeneDx in a report on Monday, June 30th. Wall Street Zen raised GeneDx from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Piper Sandler set a $120.00 price objective on GeneDx and gave the stock an "overweight" rating in a report on Monday, August 4th. Finally, Jefferies Financial Group raised GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price objective for the company in a report on Friday, May 9th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, GeneDx currently has an average rating of "Moderate Buy" and an average target price of $101.63.

Institutional Trading of GeneDx

Large investors have recently modified their holdings of the business. Lazard Asset Management LLC bought a new stake in shares of GeneDx during the 4th quarter valued at about $35,000. GAMMA Investing LLC lifted its position in GeneDx by 151.7% in the 1st quarter. GAMMA Investing LLC now owns 438 shares of the company's stock worth $39,000 after buying an additional 264 shares during the last quarter. Comerica Bank bought a new stake in GeneDx in the 4th quarter worth approximately $50,000. US Bancorp DE lifted its position in GeneDx by 3,223.5% in the 1st quarter. US Bancorp DE now owns 565 shares of the company's stock worth $50,000 after buying an additional 548 shares during the last quarter. Finally, AlphaQuest LLC lifted its position in GeneDx by 351.5% in the 2nd quarter. AlphaQuest LLC now owns 763 shares of the company's stock worth $70,000 after buying an additional 594 shares during the last quarter. Institutional investors own 61.72% of the company's stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.